Commercialization of Microfluidic Devices for Point-of-Care Diagnostics
Conference Recording Dec 01, 2013
About the SpeakerDr. Linder serves as Chief Technology Officer at OPKO Diagnostics, a company focusing on the commercialization of clinical diagnostics products, including a high-performance Point-of-Care test system (Claros1TM) and a high-specificity laboratory test for prostate cancer (4KscoreTM). He is also a co-founder of Claros Diagnostics Inc. (now part of OPKO) and co-invented the Claros technology, while being a post-doctorate fellow in George Whitesides’ laboratory at Harvard University. Dr. Linder also worked as Group Leader in microfluidics at the University of Neuchatel (Switzerland), and has served as Research Scientist at CSEM (Switzerland), a leading company in micro/nanotechnology and microelectronics. He holds a M.Sc. in Chemistry and a Ph.D. in Science from the University of Neuchatel, where he performed research in the area of microfluidic technology for immunoassays with Prof. Nico de Rooij, one of the pioneers in the field of microfluidics.
AbstractMicrofluidics is a key component to designing devices for high-performance in-vitro diagnostics tests outside the laboratory. The presentation will focus on generally applicable design rules for such devices, and a discussion of how these rules were successfully applied to the design of the Claros1TM device. The presentation will focus on the interface between microfluidics and usability, robustness (for manufacturing), cost competitiveness and clinical performance from trials.